Shares of Cipla Ltd touched a day’s excessive of Rs 1,432.55 on the BSE on 14 Might, surging as a lot as 7.94% from the earlier shut of Rs 1,327.15, at the same time as the corporate reported a pointy 55% fall in This autumn FY26 internet revenue. The rally got here after administration laid out a concrete FY27 roadmap centred on US pipeline ramp-ups and margin restoration.
In an trade submitting, Cipla revealed consolidated internet revenue for the March quarter fell to Rs 554.6 crore from Rs 1,221.8 crore a yr earlier. Income from operations slipped 2.8% to Rs 6,541.2 crore.
The pharma agency attributed the decline to decrease contribution from key US merchandise Lenalidomide and Lanreotide, elevated R&D spending, prices tied to scaling up its US manufacturing services, and the preliminary influence of geopolitical disruptions in West Asia. Web margin compressed sharply, from 22.8% in This autumn FY25 to 14.6%.
What lifted sentiment was the ahead outlook. Achin Gupta stated Cipla is getting ready for a number of respiratory launches in FY27 alongside peptide and sophisticated generic launches, with a ramp-up from its newly operational Fall River facility within the US.
The corporate just lately secured approval for the primary AB-rated generic Ventolin from its US web site, with commercialisation anticipated within the coming months.
Administration expects to cross a $1 billion annualised US income run-rate by the top of FY27 and guided for EBITDA margins of 18.5-20%, with sequential enchancment as advanced generics scale up.
For the complete yr FY26, income rose 2% to Rs 28,163 crore whereas PAT declined 26% to Rs 3,879 crore. The board really useful a remaining dividend of Rs 13 per fairness share of face worth Rs 2 for the yr ended March 2026.
At 10:48 am on 14 Might, shares had been buying and selling at Rs 1,414.40 on the BSE, up 6.57% on the day. The inventory’s 52-week excessive stands at Rs 1,672.20, whereas its 52-week low is Rs 1,165.55.
Feeling overwhelmed by the markets? Let Tradz by EquityPandit be your information. Our user-friendly app simplifies advanced knowledge and offers actionable buying and selling indicators. Obtain the app as we speak and commerce with confidence!
